Natera Gelecekteki Büyüme
Future kriter kontrolleri 4/6
Natera kazanç ve gelirin sırasıyla yıllık 58.1% ve 15.7% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 60.3% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 0.3% olacağı tahmin edilmektedir.
Anahtar bilgiler
58.1%
Kazanç büyüme oranı
60.33%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 25.1% |
| Gelir büyüme oranı | 15.7% |
| Gelecekteki özkaynak getirisi | 0.28% |
| Analist kapsamı | Good |
| Son güncelleme | 01 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Seeking Alpha • Jun 26
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise
Summary Natera delivers robust revenue growth, raising 2026 guidance to $2.74–$2.82 billion, but remains unprofitable with a high forward P/S of ~14x. Core drivers include surging test volumes in oncology and women's health, with standout performance from the Signatera MRD platform and recent regulatory wins. Despite strong fundamentals and expanding addressable markets, NTRA’s valuation appears stretched, reflecting high investor expectations for sustained hyper-growth. I assign a Hold rating, citing premium pricing and the risk that future revenue growth may not match current market optimism. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jun 22
NTRA: MRD Guideline Tailwinds Will Support 2026 Catalyst Heavy Outlook
The analyst price target for Natera has edged down slightly to $260.05 from about $260.89, as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E. They also highlight the potential uptake of Signatera following new NCCN guideline support and a continued focus on minimal residual disease testing adoption and reimbursement.Analiz Makalesi • Jun 20
Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data
Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...
Anlatı Güncellemesi • Jun 05
NTRA: MRD Leadership And FDA Approval Will Support Long-Term Trajectory
Analysts have made a modest adjustment to their outlook on Natera, with the average price target moving slightly and recent commentary highlighting the company’s position in molecular residual disease testing. Firms have set a range of targets from $245 to $260 as they balance growth reinvestment with expectations for future operating leverage.Anlatı Güncellemesi • May 22
NTRA: Molecular Residual Disease Leadership Will Support 2026 Catalyst Heavy Outlook
Natera's updated analyst price target has edged higher to about $261 from roughly $259, as analysts factor in a slightly higher fair value, a modestly adjusted discount rate and revenue growth outlook, and a stronger expected profit margin alongside a lower future P/E assumption. Analyst Commentary Recent Street research on Natera shows active recalibration of price targets, with several bullish revisions offset by a smaller number of trims.Analiz Makalesi • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...Anlatı Güncellemesi • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.
Anlatı Güncellemesi • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.Anlatı Güncellemesi • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.Anlatı Güncellemesi • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.Anlatı Güncellemesi • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.Anlatı Güncellemesi • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.Anlatı Güncellemesi • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.Anlatı Güncellemesi • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.Anlatı Güncellemesi • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.Anlatı Güncellemesi • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.Anlatı Güncellemesi • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.Anlatı Güncellemesi • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.Anlatı Güncellemesi • Nov 11
NTRA: Recent Clinical Results And Cash Flow Risks Will Shape Future Performance
Natera's analyst price target has increased significantly from $202.50 to $222.58. This reflects analysts' optimism following raised estimates and expectations for continued growth, in light of recent positive clinical trial updates and industry leadership.Anlatı Güncellemesi • Oct 27
Clinical Advances and AI Will Drive Expansion Into New Diagnostic Markets
Analysts raised their fair value estimate for Natera to $202.50 from $193.80. They cited momentum from recent clinical developments, positive trial updates, and ongoing strength in the company’s diagnostic and oncology business lines.Anlatı Güncellemesi • Sep 28
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts lowered Natera’s price target modestly to $193.80 as continued optimism around its liquid biopsy leadership and growth opportunities was tempered by renewed concerns about elevated valuation and margin outlook. Analyst Commentary Bullish analysts note Natera's leadership in liquid biopsy testing and large addressable markets in prenatal, minimal residual disease, and potential cancer screening, supporting long-term double-digit revenue growth.Anlatı Güncellemesi • Sep 04
Molecular Diagnostics And AI Integration Will Unlock New Market Opportunities
Analysts raised Natera’s price target slightly to $198.45, citing strong Q2 results, continued leadership in liquid biopsy, robust pipeline momentum, and increasing market opportunities in cancer screening and prenatal testing. Analyst Commentary Bullish analysts cited Natera's solid Q2 beat, with significant revenue upside and sustained business momentum, leading to raised outlooks for 2025.Analiz Makalesi • Aug 31
Optimistic Investors Push Natera, Inc. (NASDAQ:NTRA) Shares Up 25% But Growth Is Lacking
Natera, Inc. ( NASDAQ:NTRA ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 4,019 | 233 | 630 | 870 | 15 |
| 12/31/2027 | 3,326 | -25 | 335 | 491 | 21 |
| 12/31/2026 | 2,798 | -224 | 81 | 227 | 21 |
| 3/31/2026 | 2,501 | -226 | 72 | 211 | N/A |
| 12/31/2025 | 2,306 | -208 | 76 | 215 | N/A |
| 9/30/2025 | 2,117 | -309 | 94 | 194 | N/A |
| 6/30/2025 | 1,964 | -253 | 105 | 187 | N/A |
| 3/31/2025 | 1,831 | -190 | 85 | 153 | N/A |
| 12/31/2024 | 1,697 | -190 | 59 | 136 | N/A |
| 9/30/2024 | 1,532 | -215 | -44 | 25 | N/A |
| 6/30/2024 | 1,361 | -292 | -118 | -56 | N/A |
| 3/31/2024 | 1,209 | -365 | -197 | -139 | N/A |
| 12/31/2023 | 1,083 | -435 | -286 | -247 | N/A |
| 9/30/2023 | 989 | -499 | -311 | -270 | N/A |
| 6/30/2023 | 931 | -512 | -387 | -343 | N/A |
| 3/31/2023 | 868 | -546 | -419 | -375 | N/A |
| 12/31/2022 | 820 | -548 | -479 | -432 | N/A |
| 9/30/2022 | 776 | -546 | -498 | -449 | N/A |
| 6/30/2022 | 723 | -576 | -492 | -438 | N/A |
| 3/31/2022 | 667 | -546 | -453 | -398 | N/A |
| 12/31/2021 | 625 | -472 | -385 | -335 | N/A |
| 9/30/2021 | 565 | -408 | -354 | -310 | N/A |
| 6/30/2021 | 505 | -315 | -280 | -252 | N/A |
| 3/31/2021 | 449 | -258 | -244 | -222 | N/A |
| 12/31/2020 | 391 | -230 | -202 | -183 | N/A |
| 9/30/2020 | 362 | -189 | -139 | -124 | N/A |
| 6/30/2020 | 342 | -153 | -117 | -104 | N/A |
| 3/31/2020 | 330 | -126 | -79 | -67 | N/A |
| 12/31/2019 | 302 | -125 | N/A | -63 | N/A |
| 9/30/2019 | 286 | -121 | N/A | -61 | N/A |
| 6/30/2019 | 273 | -128 | N/A | -72 | N/A |
| 3/31/2019 | 262 | -129 | N/A | -103 | N/A |
| 12/31/2018 | 258 | -128 | N/A | -71 | N/A |
| 9/30/2018 | 243 | -144 | N/A | -86 | N/A |
| 6/30/2018 | 233 | -142 | N/A | -94 | N/A |
| 3/31/2018 | 223 | -137 | N/A | -72 | N/A |
| 12/31/2017 | 210 | -138 | N/A | -98 | N/A |
| 9/30/2017 | 207 | -128 | N/A | -99 | N/A |
| 6/30/2017 | 205 | -126 | N/A | -92 | N/A |
| 3/31/2017 | 205 | -121 | N/A | -99 | N/A |
| 12/31/2016 | 213 | -100 | N/A | -74 | N/A |
| 9/30/2016 | 221 | -81 | N/A | -49 | N/A |
| 6/30/2016 | 212 | -72 | N/A | -42 | N/A |
| 3/31/2016 | 205 | -69 | N/A | -35 | N/A |
| 12/31/2015 | 190 | -70 | N/A | -38 | N/A |
| 9/30/2015 | 187 | -46 | N/A | -23 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: NTRA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: NTRA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: NTRA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: NTRA şirketinin gelirinin (yıllık 15.7% ) US pazarından (yıllık 12.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: NTRA şirketinin gelirinin (yıllık 15.7% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: NTRA 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 0.3 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/04 04:52 |
| Gün Sonu Hisse Fiyatı | 2026/07/02 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Natera, Inc. 31 Bu analistlerden 21, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Luke Sergott | Barclays |
| Raymond Myers | Benchmark Company |